Recessive Mutations in the Putative Calcium-activated Chloride Channel Anoctamin 5 Cause Proximal LGMD2L and Distal MMD3 Muscular Dystrophies
Overview
Authors
Affiliations
The recently described human anion channel Anoctamin (ANO) protein family comprises at least ten members, many of which have been shown to correspond to calcium-activated chloride channels. To date, the only reported human mutations in this family of genes are dominant mutations in ANO5 (TMEM16E, GDD1) in the rare skeletal disorder gnathodiaphyseal dysplasia. We have identified recessive mutations in ANO5 that result in a proximal limb-girdle muscular dystrophy (LGMD2L) in three French Canadian families and in a distal non-dysferlin Miyoshi myopathy (MMD3) in Dutch and Finnish families. These mutations consist of a splice site, one base pair duplication shared by French Canadian and Dutch cases, and two missense mutations. The splice site and the duplication mutations introduce premature-termination codons and consequently trigger nonsense-mediated mRNA decay, suggesting an underlining loss-of-function mechanism. The LGMD2L phenotype is characterized by proximal weakness, with prominent asymmetrical quadriceps femoris and biceps brachii atrophy. The MMD3 phenotype is associated with distal weakness, of calf muscles in particular. With the use of electron microscopy, multifocal sarcolemmal lesions were observed in both phenotypes. The phenotypic heterogeneity associated with ANO5 mutations is reminiscent of that observed with Dysferlin (DYSF) mutations that can cause both LGMD2B and Miyoshi myopathy (MMD1). In one MMD3-affected individual, defective membrane repair was documented on fibroblasts by membrane-resealing ability assays, as observed in dysferlinopathies. Though the function of the ANO5 protein is still unknown, its putative calcium-activated chloride channel function may lead to important insights into the role of deficient skeletal muscle membrane repair in muscular dystrophies.
The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1.
Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman J, Jones A J Clin Invest. 2025; 135(4).
PMID: 39836447 PMC: 11827844. DOI: 10.1172/JCI185426.
HEK293 Cell-Based Assay to Measure the Lipid Scrambling Activity of TMEM16 Family Members.
Boccaccio A Methods Mol Biol. 2024; 2888:119-132.
PMID: 39699728 DOI: 10.1007/978-1-0716-4318-1_9.
Novel Variant in Muscular Dystrophy: Identification by Whole Genome Sequencing and Quad Analysis.
Cuk M, Unal B, Lovrencic L, Walker M, Hayes C, Abraamyan F Genes (Basel). 2024; 15(10).
PMID: 39457424 PMC: 11507210. DOI: 10.3390/genes15101300.
Yang F, Begemann A, Reichhart N, Haeckel A, Steindl K, Schellenberger E Am J Hum Genet. 2024; 111(6):1184-1205.
PMID: 38744284 PMC: 11179416. DOI: 10.1016/j.ajhg.2024.04.014.
Burden of Mendelian disorders in a large Middle Eastern biobank.
Aamer W, Al-Maraghi A, Syed N, Devadoss Gandhi G, Aliyev E, Al-Kurbi A Genome Med. 2024; 16(1):46.
PMID: 38584274 PMC: 11000384. DOI: 10.1186/s13073-024-01307-6.